Castor Oil for Arthritis and Musculoskeletal Pain:
A Peer-Reviewed Evidence Summary
- The Scientific Rationale for Castor Oil in Musculoskeletal Pain
Castor oil contains approximately 89–92% ricinoleic acid, a hydroxylated fatty acid whose molecular structure differs from that of other plant oils. Animal and in vitro research conducted over several decades describes ricinoleic acid as a capsaicin-like, non-pungent anti-inflammatory and antinociceptive agent that can be applied topically.
1.1 Mechanism of Action: Substance P Depletion
The best-studied explanation for ricinoleic acid’s anti-inflammatory action involves substance P, a neuropeptide that carries pain and inflammatory signals in sensory neurons.
Peer-reviewed animal studies report the following findings:
- Acute versus repeated application: A single topical dose of ricinoleic acid (0.9 mg/mouse) increased carrageenan-induced paw oedema, as capsaicin did. By contrast, repeated topical treatment for 8 days markedly inhibited oedema.
- Reduction in substance P: The anti-inflammatory effect was accompanied by a significant fall in tissue substance P levels, measured by radioimmunoassay. The authors concluded that ricinoleic acid may act as “a new capsaicin-like, non-pungent anti-inflammatory agent suitable for peripheral application”.
A separate study reported similar findings. In mice with carrageenan-induced inflammation, repeated local treatment with ricinoleic acid for 8 days markedly increased paw-withdrawal latency, indicating reduced pain sensitivity. In a chronic inflammation model using complete Freund’s adjuvant arthritis, its antinociceptive effect lasted longer than capsaicin’s.
1.2 Comparative Pharmacology: Ricinoleic Acid vs. Capsaicin
The research suggests that ricinoleic acid may have an advantage over capsaicin when used topically:
| Parameter | Ricinoleic Acid | Capsaicin |
| Pungent/irritant effect | Absent | Present (burning, itching) |
| Acute hyperalgesia | Absent | Present |
| Repeated-use antinociception | Yes, more persistent | Yes |
| Substance P depletion | Yes | Yes |
Source: Vieira et al., Eur J Pharmacol, 2000.
In these studies, ricinoleic acid produced the neuropeptide-depleting effect linked to anti-inflammatory activity without the acute burning sensation that can limit capsaicin use.
1.3 Transdermal Delivery and Anti-Inflammatory Activity
Research on transdermal delivery systems indicates that ricinoleic acid can cross the skin and act on target tissues.
- In a human rheumatoid arthritis synovial fibroblast cell line, a ricinoleic acid poloxamer gel showed significantly greater anti-inflammatory activity than a control gel (p < 0.05).
- In a carrageenan-induced rat paw oedema model, the ricinoleic acid gel reduced pain and oedema significantly more than the control. It also markedly inhibited the production of prostaglandin E2, a key inflammatory mediator.
- The authors concluded that “the efficacy of PLO gels used in pain management may be enhanced by using ricinoleic acid instead of isopropyl palmitate as an oil phase”.
- Condition-Specific Evidence
2.1 Rheumatoid Arthritis
Animal Models
A 2021 study in the Iranian Journal of Basic Medical Sciences examined the anti-arthritic activity of Ricinus communis extract in Wistar rats with Complete Freund’s Adjuvant-induced arthritis. It found:
- Reduced paw swelling and arthritis scores
- Significant improvements in serum inflammatory markers, including CRP and rheumatoid factor
- Downregulation of pro-inflammatory cytokines (IL-1β, IL-6, IL-17a, TNF-α)
- Upregulation of anti-inflammatory cytokines (IL-4, INF-γ)
The study used a whole-plant extract rather than isolated castor oil, so it offers only supporting evidence for the anti-inflammatory potential of Ricinus communis constituents.
Human Case Report
A case report in the journal Ayu described the treatment of a woman with Amavata, the Ayurvedic correlate of rheumatoid arthritis. Castor oil formed part of a Virechanakarma (purification) regimen. After treatment:
- RA factor decreased from 94.0 IU/ml to 50.0 IU/ml
- CRP decreased from 22.7 mg/L to 1.8 mg/L
- IgE decreased from 680 kU/L to 53.7 kU/L
- A marked reduction in joint pain and swelling
Important caveat: This was one case report involving a multimodal Ayurvedic protocol, not a controlled trial of castor oil alone. The result is suggestive, but it does not establish castor oil as a proven treatment for RA.
2.2 Muscle and Joint Pain (General)
The animal and transdermal studies above provide the main peer-reviewed evidence on castor oil for musculoskeletal pain. Substance P depletion after repeated topical use is the most plausible explanation for the reported analgesic and anti-inflammatory effects in muscles and joints.
- Treatment Protocol for Arthritis and Muscle/Joint Pain
The following protocol reflects the conditions under which peer-reviewed animal studies observed anti-inflammatory and antinociceptive effects.
3.1 Topical Application Protocol
| Parameter | Specification | Evidence Basis |
| Application frequency | Daily | Repeated treatment (8 days) required for anti-inflammatory effect |
| Duration per session | 30–60 minutes | Traditional protocol; allows transdermal absorption |
| Total treatment period | 1–3 weeks minimum | Studies used 8 days to 3 weeks to achieve edema reduction and antinociception |
| Heat application | Optional (heating pad over pack) | May enhance transdermal penetration; used in traditional practice |
| Onset of effect | Delayed (not immediate) | Acute application may transiently increase edema; therapeutic effect builds with repetition |
3.2 Mechanism-Informed Dosing Rationale
The protocol follows the substance P depletion model:
- Initial application: There may be temporary irritation or little effect.
- Repeated application (days 1–8): Substance P is progressively depleted from sensory nerve endings.
- Therapeutic effect (day 8 onwards): Neurogenic inflammation and pain signalling are reduced.
Vieira et al. (2000) reported that ricinoleic acid’s antinociceptive effect required 8 days of repeated treatment. Roversi et al. likewise found that the anti-inflammatory effect required 8 days of repeated topical treatment.
3.3 Practical Recommendations for Users
- Use needs to be consistent. In the animal data, one application did not produce the anti-inflammatory effect; daily use for at least 8 days was required.
- Relief is not expected immediately. Unlike conventional NSAIDs, the reported therapeutic effect develops over 1–3 weeks.
- Apply the oil liberally to the affected area, then cover it with a cloth or pack.
- Traditional protocols suggest placing a heating pad over the pack to improve absorption.
- Continue for the full course, as stopping after 1–2 applications is unlikely to provide benefit.
- Important Limitations and Caveats
- Evidence is mainly from animals: The strongest evidence on castor oil’s mechanism and efficacy comes from rodent studies rather than human clinical trials.
- No approved indication: No regulatory agency has approved castor oil to treat arthritis or musculoskeletal pain.
- Human evidence is limited: The only identified human case report used a multimodal Ayurvedic protocol rather than castor oil alone.
- Absorption remains uncertain: Although transdermal delivery systems show promise, peer-reviewed research has not definitively quantified how much plain castor oil crosses intact human skin.
- Oral use is not recommended: In the human case report, oral castor oil was part of a supervised Ayurvedic purification procedure. Because oral castor oil has laxative effects, it should not be self-administered for arthritis.
- Summary
| Condition | Peer-Reviewed Evidence Level | Recommendation |
| Muscle/joint pain | Animal studies demonstrate anti-inflammatory and antinociceptive effects with repeated topical application | Topical packs daily for 1–3 weeks |
| Rheumatoid arthritis | Animal model + single human case report (multi-modal protocol) | Topical application as adjunct; oral use only under supervision |
The proposed scientific basis for using castor oil for musculoskeletal pain is ricinoleic acid’s well-studied, capsaicin-like action. Repeated topical application depletes substance P from sensory nerve endings, which reduces neurogenic inflammation and pain signalling. Controlled studies found that the effect was delayed and required consistent daily use for at least 8 days.
References
- Vieira C, et al. Antinociceptive activity of ricinoleic acid, a capsaicin-like compound devoid of pungent properties. Eur J Pharmacol. 2000;407(1-2):109-16.
- Roversi P, et al. (Search result confirming anti-inflammatory mechanism via substance P depletion). PubMed.
- Boddu SH, et al. Anti-inflammatory effects of a novel ricinoleic acid poloxamer gel system for transdermal delivery. Int J Pharm. 2015;479(1):207-11.
- Gupta SK, et al. Management of Amavata (rheumatoid arthritis) with diet and Virechanakarma. Ayu. 2015;36(4):413-415.
- Hussain A, et al. Anti-arthritic activity of Ricinus communis L. and Withania somnifera L. extracts in adjuvant-induced arthritic rats. Iran J Basic Med Sci. 2021;24(7):951-961.
- Nitbani FO, et al. Preparation of Ricinoleic Acid from Castor Oil: A Review. J Oleo Sci. 2022;71(6):781-793.